Zydus launches Sitaglyn and Siglyn for the management of Type 2 diabetes

The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes

Mandaviya calls for collaboration to eliminate vector borne diseases

Capnopharm to acquire operational assets of Capnomed

Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.

Dr. Reddy's Laboratories updates on PAI of formulations facility

The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.

Lupin’s Somerset manufacturing plant Receives EIR from US FDA

The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated

Glenmark launches Sitagliptin and its FDC at affordable price

These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens

Lonza to build large-scale fill & finish facility in Switzerland

The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026

Eugia Pharma receives USFDA approval for Triamcinolone Acetonide Injectable Suspension

This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Wacker to expand mRNA-based actives capacity at Halle, Germany

Company is investing more than €100 million in the expansion of the Halle site

Cipla updates on US FDA product-specific pre-approval inspection

The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at Indore plant.